Skip to main content
SpringerLink
Log in

Die junge Mammakarzinompatientin mit Kinderwunsch

The young breast cancer patient desiring children

  • Leitthema
  • Published:
Gynäkologische Endokrinologie Aims and scope

Zusammenfassung

Das Mammakarzinom ist die häufigste Krebserkrankung der Frau, zunehmend sind auch Frauen betroffen, die ihre Familienplanung noch nicht abgeschlossen haben. Eine der gravierenden Nebenwirkungen der bei jungen Frauen häufig eingesetzten Chemotherapien ist die Schädigung der Ovarialfunktion, die u. U. bis zum Verlust der Fertilität führen kann. Eine frühzeitige Beratung über die möglichen fertilitätserhaltenden Maßnahmen ermöglicht in der Regel die Integration dieser Maßnahmen in das onkologische Therapieregime, ohne dass es zu einer Verzögerung des Behandlungsbeginns kommt. Nach einer lokal begrenzten Brustkrebserkrankung gibt es laut der aktuellen Datenlage keinen Grund, einer betroffenen Frau von einer Schwangerschaft abzuraten. Die Schwangerschaft scheint keinen negativen Einfluss auf die Prognose des weiteren Krankheitsverlaufs zu haben. Eine Erhöhung des Anomalierisikos durch Substanzen, die in der onkologischen Therapie verwendet werden, ist für die Nachkommen von Mammakarzinompatientinnen nicht zu befürchten, wenn die Schwangerschaft nach Absetzen der Medikation und unter Beachtung der Auswaschphase eingetreten ist.

Abstract

Breast cancer is the most common cancer in women, and an increasing number of women who have not completed their family planning are being affected. One of the most serious side effects of chemotherapy is damage to the ovaries and possible loss of fertility. Early counselling on the possibility of fertility preservation methods normally allows integration of these methods into the oncological treatment regimen, without delaying the start of treatment. According to current data, there is no reason to advise a woman with localised breast cancer against becoming pregnant. The pregnancy does not appear to have any negative effects on the further disease prognosis. An increase in the risk of anomalies as a result of the chemotherapy agents used should not be feared if the pregnancy occurs after the medication has been stopped and the drug washout period is observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Arbeitsgemeinschaft Gynäkologische Onkologie (2011) Mamma-Leitlinien. http://www.ago-online.de/index.php?lang=de&site=mamma_guide_topical&topic=mamma_guide

  2. Azim AA, Costantini-Ferrando M, Oktay K (2008) Safety of fertility preservation by ovarian stimulation with letrozol and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 26:2630–2635

    Google Scholar 

  3. Azim HA Jr, Santoro L, Pavlidis N et al (2010) Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer 47:74–83

    Article  PubMed  Google Scholar 

  4. Badawy A, Elnashar A, El-Ashry M, Shahat M (2009) Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91:694–697

    Article  PubMed  CAS  Google Scholar 

  5. Byrne J, Rasmussen SA, Steinhorn SC et al (1998) Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. Am J Hum Genet 62:45–52

    Article  PubMed  CAS  Google Scholar 

  6. Dodds L, Marrett LD, Tomkins DJ et al (1993) Case-control study of congenital anomalies in children of cancer patients. BMJ 307:164–168

    Article  PubMed  CAS  Google Scholar 

  7. Gelber S, Coates AS, Goldhirsch A et al (2001) Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol 19:1671–1675

    Google Scholar 

  8. Gerber B, Minckwitz G von, Stehle H et al (2011) Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 29:2334–2341

    Google Scholar 

  9. Isaacs RJ, Hunter W, Clark K (2001) Tamoxifen as systemic treatment of advanced breast cancer during pregnancy – case report and literature review. Gynecol Oncol 80:405–408

    Article  PubMed  CAS  Google Scholar 

  10. Ives A, Saunders C, Bulsara M, Semmens J (2006) Pregnancy after breast cancer: Population based study. BMJ 334:194

    Article  PubMed  Google Scholar 

  11. Kreienberg R, Kopp I, Albert U et al (2008) German Cancer Society and German Society for Gynecology and Obstetrics. Interdisciplinary S3 guidelines for the diagnosis, treatment and follow-up care of breast cancer. 1st updated version. W. Zuckschwerdt Verlag GmbH, München

  12. Larsen EC, Müller J, Schmiegelow K (2003) Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 88:5307–5314

    Google Scholar 

  13. Meistrich M, Byrne J (2002) Genetic disease in offspring of long-term survivors of childhood and adolescent cancer treated with potentially mutagenic therapies. Am J Hum Genet 70:1069–1071

    Article  PubMed  Google Scholar 

  14. Mueller BA, Simon MS, Deepen D et al (2003) Childbearing and survival after breast carcinoma in young women. Cancer 98:1131–1140

    Article  PubMed  Google Scholar 

  15. Mulvihill JJ, McKeen EA, Rosner F et al (1987) Pregnancy outcome in cancer patients. Experience in a large cooperative group. Cancer 60:1143–1150

    Article  PubMed  CAS  Google Scholar 

  16. Oktay K, Hourvitz A, Sahin G et al (2006) Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 91:3885–3890

    Google Scholar 

  17. Robert Koch-Institut (2010) Krebs in Deutschland 2005/2006. Häufigkeiten und Trends. http://www.rki.de/cln_117/nn_205770/sid_5890D683E1F727B23804B4FE79306FFD/DE/Content/GBE/DachdokKrebs/krebs__node.html?__nnn_ true

  18. Rosendahl M, Timmermans Wielenga V, Nedergaard L et al (2011) Cryopreservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in ovarian tissue from patients with breast cancer. Fertil Steril 95:2158–2161

    Article  PubMed  Google Scholar 

  19. Sánchez-Serrano M, Novella-Maestre E, Roselló-Sastre E et al (2009) Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservation. Hum Reprod 24:2238–2243

    Article  PubMed  Google Scholar 

  20. Sankila R, Olsen JH, Anderson H et al (1998) Risk of cancer among offspring of childhood-cancer survivors. Association of the Nordic Cancer Registries and the Nordic Society of Paediatric Haematology and Oncology. N Engl J Med 338:1339–1344

    Google Scholar 

  21. Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 4:2738–2746

    Google Scholar 

  22. Schover LR, Rybicki LA, Martin BA, Bringelsen KA (1999) Having children after cancer. A pilot survey of survivors‘ attitudes and experiences. Cancer 86:697–709

    Article  PubMed  CAS  Google Scholar 

  23. Valachis A, Tsali L, Pesce LL et al (2011) Safety of pregnancy after primary breast carcinoma in young women: a meta-analysis to overcome bias of healthy mother effect studies. Obstet Gynecol Surv 65:786–793

    Article  Google Scholar 

  24. Velentgas P, Daling JR, Malone KE et al (1999) Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer 85:2424–2432

    Article  PubMed  CAS  Google Scholar 

  25. Wolff M von, Montag M, Dittrich R et al (2011) Fertility preservation in women – a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin’s lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet 284:427–435

    Article  Google Scholar 

  26. Walshe JM, Denduluri N, Swain S (2006) Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24:5769–5779

    Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Gynäkologische Endokrinologie und Reproduktionsmedizin, Universitäts-Frauenklinik Tübingen, Calwerstr. 7, 72076, Tübingen, Deutschland

    B. Lawrenz, T. Fehm, S. Hübner, E.-M. Grischke & M. Henes

Authors
  1. B. Lawrenz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Fehm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Hübner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E.-M. Grischke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Henes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Lawrenz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lawrenz, B., Fehm, T., Hübner, S. et al. Die junge Mammakarzinompatientin mit Kinderwunsch. Gynäkologische Endokrinologie 10, 110–115 (2012). https://doi.org/10.1007/s10304-011-0458-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10304-011-0458-2

Schlüsselwörter

Keywords

Search

Navigation